12 related articles for article (PubMed ID: 38754016)
1. Evaluation of Homologous Recombination Deficiency in Ovarian Cancer.
Ratnaparkhi R; Javellana M; Jewell A; Spoozak L
Curr Treat Options Oncol; 2024 Feb; 25(2):237-260. PubMed ID: 38300479
[TBL] [Abstract][Full Text] [Related]
2. The integration of BRCA testing into oncology clinics.
Percival N; George A; Gyertson J; Hamill M; Fernandes A; Davies E; Rahman N; Banerjee S
Br J Nurs; 2016 Jun; 25(12):690-4. PubMed ID: 27345073
[TBL] [Abstract][Full Text] [Related]
3. Homologous recombination deficiency in ovarian cancer: a review of its epidemiology and management.
da Cunha Colombo Bonadio RR; Fogace RN; Miranda VC; Diz MDPE
Clinics (Sao Paulo); 2018 Aug; 73(suppl 1):e450s. PubMed ID: 30133561
[TBL] [Abstract][Full Text] [Related]
4. Homologous recombination deficiency should be tested for in patients with advanced stage high-grade serous ovarian cancer aged 70 years and over.
Pitiyarachchi O; Ansell PJ; Coleman RL; Dinh MH; Holman L; Leath CA; Werner T; DiSilvestro P; Morgan M; Tew W; Lee C; Cunningham M; Newton M; Edraki B; Lim P; Barlin J; Spirtos NM; Tewari KS; Edelson M; Reid T; Carlson J; Friedlander M
Gynecol Oncol; 2024 May; 187():221-226. PubMed ID: 38821039
[TBL] [Abstract][Full Text] [Related]
5. Genetic Testing Utilization: Discrepancies Between Somatic and Germline Results in Patients With Cancer Reviewed at the UW Health Precision Medicine Molecular Tumor Board.
Horn IP; Zakas AL; Smith-Simmer KJ; Birkeland LE; Sundstrom R; Burkard ME; Weiss JM
JCO Precis Oncol; 2024 May; 8():e2300466. PubMed ID: 38810171
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic applications of germline testing for cancer predisposition genes in Asia in the real world.
Cheo SW; Ong PY; Ow SGW; Chan GHJ; Tan DSP; Lim YW; Kong HL; Wong ALA; Lim SE; Walsh RJ; Wong ASC; Low JJH; Ngoi NYL; Lim JSL; Lee SC
ESMO Open; 2024 Jun; 9(6):103482. PubMed ID: 38833967
[TBL] [Abstract][Full Text] [Related]
7. Genetic Counselling, BRCA1/2 Status and Clinico-pathologic Characteristics of Patients with Ovarian Cancer before 50 Years of Age.
Cvelbar M; Hocevar M; Novakovic S; Stegel V; Perhavec A; Krajc M
Radiol Oncol; 2017 Jun; 51(2):187-194. PubMed ID: 28740454
[TBL] [Abstract][Full Text] [Related]
8. MAGENTA: a Multinational patient survey assessing the Awareness, perceptions and unmet needs in GENetic Testing and counselling among patients with breAst cancer.
Powell S; Artigas M; Borovova I; Gadiya P; Hsu A; Kaur R; Kidd L; Rosenfeld D; Saeed MM; Scarelli E; Youssef MW
Front Oncol; 2024; 14():1380349. PubMed ID: 38807767
[TBL] [Abstract][Full Text] [Related]
9. Feasibility and cost-effectiveness of genetic counselling for all patients with newly diagnosed ovarian cancer: a single-centre retrospective study.
Schlootz S; Saner FAM; Rabaglio M; Imboden S; Wampfler J
Swiss Med Wkly; 2024 Apr; 154():3386. PubMed ID: 38754016
[TBL] [Abstract][Full Text] [Related]
10.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
11.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
